When to Thrombolyze in Light of New Evidence?

Dear <<Last Name>>

In light of recent results from the MR-CLEAN NO IV trial, which failed to show superiority or non-inferiority of EVT alone to combined lysis and EVT, the current significance of thrombolysis in the setting of a large vessel occlusion (LVO) is unknown/debatable.

The role of Tenecteplase TNK in the presence of LVO has not been studied in a large randomized controlled trial. While current guidelines recommend use of Tenecteplase (0.25mg/kg) over alteplase as level/class IIb evidence in patients undergoing EVT, the additional utility of Tenecteplase in patients with LVOs is yet to be understood.

This brief focused survey will enable us to gain insights into how the stroke community thinks about this issue and the role of Tenecteplase in this setting.

Link to When-to-AcT Survey
There are 15 questions in this survey which takes approximately 10 minutes to complete and is accessible from any device or browser. All replies are anonymous.

Thanks so much for your participation and time!

 Dr. Bijoy Menon

Nima Kashani | Nishita Singh | Mohammed Almekhlafi
The Calgary Stroke Program
ASP Website
Copyright © 2021 Calgary Stroke Program, All rights reserved.

Want to change how you receive these emails?
You can
update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp